Contact Information: Contacts: MDRNA, Inc.: Mark Bales, Ph.D. IP Counsel (425) 908-3634 mbales@mdrnainc.com Westwicke Partners (Investors): Stefan Loren, Ph.D. (443) 213-0507 sloren@westwicke.com John Woolford (443) 213-0506 john.woolford@westwicke.com McKinney|Chicago (Media): Alan Zachary (312) 944-6784 x 316 (708) 707-6834 azachary@mckinneychicago.com
MDRNA, Inc. Announces Patent Allowance Covering Methods for Targeted siRNA Delivery to the Lung
Patent Strengthens MDRNA's RNAi Delivery IP Estate
| Source: MDRNA, Inc.
BOTHELL, WA--(Marketwire - December 17, 2009) - MDRNA, Inc. (NASDAQ : MRNA ), a leading
RNAi-based drug discovery and development company, today announced that the
U.S. Patent and Trademark Office (USPTO) has allowed patent application
U.S. 11/627,863 covering methods for the delivery of a broad array of
compounds with pharmacological (biological) activity, including siRNAs,
using proprietary targeting peptides that have preferential binding
affinity for lung tissue.
"The development of cell and tissue specific delivery technologies remains
a key goal in the field of RNAi therapeutics," said Barry Polisky, Ph.D.,
Chief Scientific Officer of MDRNA. "This patent allowance demonstrates
MDRNA's ability to develop targeting technologies for the delivery of RNAi
therapeutics by using highly specific peptides from its patented phage
display library. We will combine these peptides with our proprietary DiLA2
delivery platform technology to create highly site-specific novel
therapies."
The peptides were identified using the Company's proprietary Trp Cage Phage
Display library (J Biol Chem. 2007 282(13):9813; U.S. patent 7,329,725).
The Trp Cage motif is highly structured allowing for the identification of
peptides with high binding affinity for specific cell or tissue types, and
avoids the limitations and weak binding often associated with linear
peptide libraries. This technology is directly applicable to the Company's
DiLA2 delivery platform as peptides are readily conjugated to the amino
acid scaffold of a DiLA2. Peptides capable of directed delivery are
expected to further improve the delivery efficiency of UsiRNAs, which have
demonstrated significant knockdown of target genes in mouse models of liver
and bladder cancer, and in non-human primates.
"Our scientific team continues to develop a broad set of delivery
strategies for RNAi-based therapies," said J. Michael French, President and
CEO of MDRNA. "With our ongoing collaboration with the University of
Helsinki for the discovery of novel peptides from our proprietary Trp Cage
Library, we expect further advances for effective targeting and delivery of
siRNAs. The identification of additional peptides with high affinity to
specific cell types, including certain cancers, is expected and will
further expand the Company's patent estate."
A patent allowance confirms the substantive examination of a patent
application and will result in a final issuance of a U.S. patent after an
administrative process is completed.
About MDRNA's Technology
MDRNA has a broad intellectual property estate that encompasses four key
RNAi technology platforms: siRNA constructs, chemistry, nucleic acid
delivery, and gene targets. The MDRNA-owned siRNA constructs and chemistry
include its proprietary UsiRNA construct, which is a duplex siRNA
chemically modified with non-nucleotide acyclic monomers (UNAs), and is
distinct from the standard siRNA construct used by others in the industry.
UsiRNAs are fully recognized by the RNAi machinery and provide for potent
RNAi activity while specific placement of UNAs in a duplex siRNA minimizes
potential off-target effects by the guide strand and reduces undesired
passenger strand activity. Furthermore, UsiRNAs escape the surveillance
mechanisms associated with cytokine induction, and provide protection from
nuclease degradation.
The MDRNA delivery platforms include DiLA2 and nanoparticle forming
peptides. DiLA2 is a MDRNA proprietary delivery platform of novel synthetic
di-alklylated amino acid compounds used to make liposomal delivery
formulations. The DiLA2 platform enables MDRNA to tailor the charge,
linker and acyl chains of amino acids in order to configure liposomes for
delivery to target tissues of interest. In addition, the platform is
designed to permit attachment of various peptides and other targeting
molecules to improve a variety of delivery characteristics. The MDRNA
peptide nanoparticle platform includes exclusively in-licensed and
developed IP surrounding the use of peptides for nanoparticle formulations
that increase cellular uptake and endosomal release of siRNAs. MDRNA is
currently biopanning its patented phage display library to identify
additional peptides for targeted delivery, cellular uptake and endosomal
release of siRNA.
MDRNA owns or controls 4 issued patents and has more than 40 pending patent
applications, 126 pending foreign patent applications and 6 PCT
applications.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based
compounds and drug delivery technologies that together provide superior
therapeutic options for patients. Over the past decade, we have developed
substantial capabilities in molecular biology, cellular biology, lipid
chemistry, peptide chemistry, pharmacology and bioinformatics, which we are
applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual
property have rapidly enabled us to become a leading RNAi-based
therapeutics company with a pre-clinical pipeline in oncology. Through our
capabilities, expertise and know-how, we are incorporating multiple RNAi
technologies as well as peptide- and lipid-based delivery approaches into a
single integrated drug discovery platform that will be the engine for our
clinical pipeline as well as a versatile platform for establishing broad
therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer
and more effective RNAi-based therapeutics while aggressively building upon
our broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statements
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or suggested
in any forward-looking statements are contained in MDRNA's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.